natural killer cell therapy
/ Chongqing Sidemu Biotechnology Technology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 27, 2020
A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19
(clinicaltrials.gov)
- P1/2; N=90; Recruiting; Sponsor: Chongqing Public Health Medical Center
New P1/2 trial
1 to 1
Of
1
Go to page
1